Overview

A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging

Status:
Completed
Trial end date:
2009-12-03
Target enrollment:
Participant gender:
Summary
This study is being conducted to assess the potential anti-inflammatory effects of a 3-month treatment with GW856553, on the inflammatory activity within the aorta and carotid plaques, as assessed by FDG-PET/CT.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline